Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SENP1 | Q9P0U3 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CCKBR | P32239 | 8/20 | 0.48 |
| ▸ | CCKAR | P32238 | 4/20 | 0.48 |
| ▸ | BRD4 | O60885 | 6/20 | 0.45 |
| ▸ | BRD2 | P25440 | 6/20 | 0.45 |
| ▸ | BRD3 | Q15059 | 6/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7552265 | 1.00 | SENP1 (0.51) | SENP1ALDH1A1MAPTHTTHSD17B10 | |
| SCHEMBL7547418 | 0.92 | SENP1 (0.54) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL7547410 | 0.92 | SENP1 (0.54) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL7547434 | 0.91 | SENP1 (0.50) | SENP1ALDH1A1MAPTHTTHSD17B10 | |
| SCHEMBL7547426 | 0.91 | SENP1 (0.50) | SENP1ALDH1A1MAPTHTTHSD17B10 | |
| SCHEMBL7573241 | 0.91 | SENP1 (0.51) | SENP1ALDH1A1MAPTHTTHSD17B10 | |
| SCHEMBL7573232 | 0.91 | SENP1 (0.51) | SENP1ALDH1A1MAPTHTTHSD17B10 | |
| SCHEMBL7550781 | 0.91 | SENP1 (0.53) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL7550774 | 0.91 | SENP1 (0.53) | SENP1CCKBRBRD4BRD2BRD3 | |
| SCHEMBL7544196 | 0.90 | SENP1 (0.49) | SENP1ALDH1A1MAPTHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-05 | — | — | US | disclosed |
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | disclosed |
| US-6291452-B1 | CHOLECYSTOKININ ANTAGONISTS. | FUJISAWA PHARMACETICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0934282-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| US-5925805-A | INTRODUCING INTO PLANT CELL A DNA CONSTRUCT COMPRISING A NUCLEOTIDE SEQUENCE ENCODING A PLANT CYTOSOLIC ACETYL-COA CARBOXYLASE OPERATIVELY LINKED TO A NUCLEOTIDE SEQUENCE ENCODING A PLASTID TRANSIT PEPTIDE, GROWING CELL INTO PLANT | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) | 1999-07-20 | — | — | US | disclosed |
| WO-1998015535-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | SENP1 3511/4885ALDH1A1 1169/4885MAPT 4445/4885 |
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | SENP1 3511/4885ALDH1A1 1169/4885MAPT 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.